Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions Patents (Class 424/1.11)
  • Patent number: 11065339
    Abstract: Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: July 20, 2021
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Sarah E. Poplawski
  • Patent number: 11065350
    Abstract: The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. In some embodiments, the present invention provides a method for the treatment or prevention of inflammation and/or infection. In some embodiments, the present invention provides methods for monitoring the effect of inflammation and/or infection treatment, and/or methods for monitoring an inflammation and/or infection treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for an inflammation and/or infection treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug for the treatment of inflammation and/or infection.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: July 20, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Mark Dunphy, Gabriela Chiosis
  • Patent number: 11065351
    Abstract: Disclosed are compositions and methods for diagnosing eosinophilic esophagitis in a subject. Also disclosed are methods for monitoring the course of eosinophilic esophagitis in a subject before, during, and after treatment. In another aspect, disclosed is a method of diagnosing eosinophilic esophagitis or eosinophilic diseases in a subject, comprising detecting an eosinophil granule protein in the mucosal tissue of the esophagus or other organs in a subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 20, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Leonard F. Pease, Hedieh Saffari, Gerald J. Gleich, Kristin M. Leiferman, Kathryn A. Peterson, Russell Morris Condie
  • Patent number: 11059802
    Abstract: The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 13, 2021
    Assignee: VisEn Medical, Inc.
    Inventors: Kevin Groves, Bagna Bao
  • Patent number: 11058781
    Abstract: The present invention relates to compounds that may be used for binding and imaging tau aggregates and related beta-sheet aggregates including, besides others, beta-amyloid aggregates or alpha-synuclein aggregates.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: July 13, 2021
    Inventors: Luca Gobbi, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 11053222
    Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: July 6, 2021
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
  • Patent number: 11052163
    Abstract: The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 6, 2021
    Assignee: Washington University
    Inventors: Gregory M. Lanza, Samuel I. Achilefu, Grace Hufang Cui
  • Patent number: 11052160
    Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion DA and DB).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 6, 2021
    Assignee: Avelas Biosciences, Inc.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Patent number: 11051713
    Abstract: Apparatus, including a ferromagnetic sheet and at least one radiator, mounted in proximity to the ferromagnetic sheet and configured to radiate a magnetic field into a region in proximity thereto. The apparatus further includes a solid sheet of thermal insulation, mounted between the ferromagnetic sheet and the at least one radiator so as to prevent transfer of thermal energy from the at least one radiator to the ferromagnetic sheet.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: July 6, 2021
    Assignee: BIOSENSE WEBSTER (ISRAEL) LTD.
    Inventors: Alon Boumendil, Vadim Gliner, Assaf Govari
  • Patent number: 11027031
    Abstract: The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of the kit for radiolabelling a targeting agent, and a method for radiolabelling a targeting agent with gallium-68 using the kit.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: June 8, 2021
    Assignee: ANMI S.A.
    Inventors: Ludovic Wouters, Geoffroy Kaisin, André Luxen, Marc Léonard, Samuel Voccia
  • Patent number: 11021756
    Abstract: The present invention discloses the use of miR-4714, miR-4521, and miR-1292 as diagnostic markers for osteosarcoma. High-throughput sequencing and QPCR experiments prove that the levels of miR-4714, miR-4521, and miR-1292 in the blood of normal and osteosarcoma patients are significantly different, and therefore miR-4714, miR-4521, and miR-1292 can be used as a molecular marker for the diagnosis of osteosarcoma for developing products for the diagnosis of osteosarcoma. The diagnostic product has the following advantages: non-invasive, rapid, sensitive, and has broad application prospects in clinical practice.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 1, 2021
    Inventor: Zuozhang Yang
  • Patent number: 11014964
    Abstract: The invention provides a peptide amide compound represented by the general general formula (I), a preparation method thereof, and a medical application thereof. The compound has a novel structure, better biological activity, and better analgesic effect.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 25, 2021
    Assignee: Sichuan Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen Zhang, Anbang Huang, Fei Ye, Longbin Huang, Zhenggang Huang, Jianmin Wang, Yonggang Wei, Pangke Yan, Wei Zheng
  • Patent number: 11007286
    Abstract: The present invention encompasses compositions comprising two spectrally distinct radionuclides separated by a site susceptible to cleavage. Compositions of the invention may be used to detect enzyme activity and/or image diseases associated with said enzyme activity.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: May 18, 2021
    Assignee: Washington University
    Inventors: Samuel Achilefu, Kvar Black
  • Patent number: 10994032
    Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: May 4, 2021
    Assignee: TRT Innovations APS
    Inventors: Andreas Kjaer, Morten Persson, Michael Ploug
  • Patent number: 10988534
    Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: April 27, 2021
    Assignees: Memorial Sloan Kettering Cancer Center, Massachusetts Institute of Technology
    Inventors: Sarah Cheal, Hong Xu, Steven Larson, Nai-Kong Cheung, Karl Dane Wittrup, Alice Tzeng
  • Patent number: 10981866
    Abstract: The present invention is directed to a compound of Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula III wherein the definitions of R1-R12 and L1-L4 are provided in the disclosure, wherein R13 is a chelating group comprising 177Lu, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 20, 2021
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Patent number: 10981892
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: April 20, 2021
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 10973813
    Abstract: The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
  • Patent number: 10975073
    Abstract: The invention relates to small molecule imaging tools.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: April 13, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Patent number: 10967076
    Abstract: A method for magnetic resonance (MR) imaging or spectroscopy on a MR scanner to detect tissue physiological parameters in one or more tissue areas in a human or non-human subject includes administering to the subject a contrast enhancing physiologically tolerable amount of a sugar that is non-labeled, subjecting the subject to an MR procedure capable of generating MR signals encoding at least one tissue area in the subject in which the sugar either passes or is taken up, detecting a temporal variation in the MR signals in the at least one tissue area after the administering the sugar, determining at least one tissue-related parameter from the temporal variation, and ascertaining whether the at least one tissue-related parameter is abnormal.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: April 6, 2021
    Assignee: The Johns Hopkins University
    Inventors: Peter C. Van Zijl, Dmitri Artemov, Kannie Wai Yan Chan, Yoshinori Kato, Michael T. McMahon, Guanshu Liu
  • Patent number: 10961193
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 30, 2021
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • Patent number: 10953113
    Abstract: An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric acid (18F-FGA), or a pharmaceutically-acceptable salt thereof. The imaging agent may be disposed in a pharmaceutically-acceptable excipient, carrier, diluent, or vehicle. The imaging agent may be contained within a kit. The disclosure includes in at least one embodiment a method of preparing a radiopharmaceutical such as 18F-FGA for use in imaging.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 23, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
    Inventors: Vibhudutta Awasthi, Hailey Houson, Gregory Nkepang
  • Patent number: 10952943
    Abstract: The disclosure provides a zinc-arginine complex, methods of making the same, and methods of using the same in oral care compositions.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: March 23, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Zhigang Hao, Chi-Yuan Cheng, Tatiana Brinzari, Long Pan, Ravi Subramanyam
  • Patent number: 10947275
    Abstract: The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticle pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 16, 2021
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Ayelet David, Gonen Ashkenasy, Yosi Shamay
  • Patent number: 10933251
    Abstract: Systems and devices for pulsed heating of the ST36 acupoint and/or other acupoint(s) by noninvasive transcutaneous magnetic induction heating towards (1) ameliorating cognitive impairment arising, for example, from head-injury, stroke, and neurodegenerative diseases such as Alzheimer's; (2) helping to prevent neurodegenerative diseases; (3) preventing and treating age-related cognitive decline; and (4) preventing and treating depression manifesting, for example, as Major Depressive Disorder, Dysthymic Disorder, or Adjustment Disorder with Depressed Mood.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: March 2, 2021
    Inventors: Jonathan M Borkum, Mohsen Shahinpoor
  • Patent number: 10932706
    Abstract: Methods and systems for targeting, accessing and diagnosing diseased lung compartments are disclosed. The method comprises introducing a diagnostic catheter with an occluding member at its distal end into a lung segment via an assisted ventilation device; inflating the occluding member to isolate the lung segment; and performing a diagnostic procedure with the catheter while the patient is ventilated. The proximal end of the diagnostic catheter is configured to be attached to a console. The method may also comprise introducing the diagnostic catheter into the lung segment; inflating the occluding member to isolate the lung segment; and monitoring blood oxygen saturation. The method may further comprise introducing the diagnostic catheter into the lung segment; determining tidal flow volume in the lung segment; determining total lung capacity of the patient; and determining a flow rank value based on the tidal flow volume of the lung segment and the total lung capacity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 2, 2021
    Assignee: Pulmonx Corporation
    Inventors: Surag Mantri, Srikanth Radhakrishnan
  • Patent number: 10933146
    Abstract: The disclosure relates in some aspects to imaging agents, and in particular, imaging agents for sensing of calcium signaling. According to some embodiments of the disclosure, contrast agents for magnetic resonance imaging and related technologies are provided, and methods of making and using the contrast agents.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 2, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Alan Pradip Jasanoff, Ali Barandov, Benjamin B. Bartelle
  • Patent number: 10925980
    Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: February 23, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Zheng-Rong Lu, Zheng Han
  • Patent number: 10925981
    Abstract: The present invention provides a hexa-lactoside-triazanonane triacetic acid (NOTA) derivative, a method for radiolabeling a hexa-lactoside positron emission tomography (PET) imaging agent for a liver receptor with Ga-68, and a hexa-lactoside PET imaging agent for a liver receptor. The hexa-lactoside-NOTA derivative is a conjugate of six chains of lactose with NOTA obtained by conjugating hexa-lactoside to a chelating agent p-thiocyanate-benzyl-triazanonane diacetic acid-glutamic acid in the presence of triethyl amine/dimethyl formamide as a solvent. The radiolabeling method comprises labeling with Ga-68 at room temperature. According to the present invention, the labeling effect is stable, the labeling efficiency of the labeled product is greater than 95%, the labeled product is highly stable and the radiochemical purity is still greater than 90% after 4 hours.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 23, 2021
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C
    Inventors: Wuu-Jyh Lin, Mei-Hui Wang, Hung-Man Yu, Kun-Liang Lin, Yan-Feng Jiang, Rui-Yu Chen
  • Patent number: 10898598
    Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 26, 2021
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John L. Joyal, Genliang Lu
  • Patent number: 10900037
    Abstract: Provided herein is the two component self-assembly single wall nanotube system and the single wall nanotube construct that is the second component. The two component self-assembly single wall nanotube system has a morpholino oligonucleotide with a targeting moiety followed by a single wall nanotube construct with second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: January 26, 2021
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Patent number: 10898593
    Abstract: Multivalent CT or MR contrast agents and methods of making and using thereof are described herein. The agents contain a moiety, such as a polymer, that provides multivalent attachment of CT or MR contrast agents. Examples include, but are not limited to, multivalent linear polymers, branched polymers, or hyperbranched polymers, such as dendrimers, and combinations thereof. The dendrimer is functionalized with one or more high Z-elements, such as iodine. The high Z-elements can be covalently or non-covalently bound to the dendrimer. The dendrimers are confined in order to enhance CT contrast. In some embodiments, the moiety is confined by encapsulating the dendrimers in a material to form particles, such as nanoparticles. In other embodiments, the dendrimer is confined by conjugating the moiety to a material, such as a polymer, which forms a gel upon contact with bodily fluids.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 26, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Tarek Fahmy, Albert Sinusas, Dongin Kim
  • Patent number: 10877021
    Abstract: A device for biological material detection includes a substrate; a through-hole through which a biological material to be tested passes, the through-hole being formed in the substrate; a molecule that interacts with the biological material to be tested passing through, the molecule being formed in the through-hole; a first chamber member that forms, with at least the surface including the through-hole on one surface side of the substrate, a first chamber to be filled with electrolyte; and a second chamber member that forms, with at least the surface including the through-hole on the other surface side of the substrate, a second chamber to be filled with electrolyte. The biological material to be tested is identified by the waveform of the ion current (passage time, shape, etc.) when the biological material to be tested passes through the through-hole.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 29, 2020
    Assignees: OSAKA UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Makusu Tsutsui, Kazumichi Yokota, Masateru Taniguchi, Tomoji Kawai, Mina Okochi, Masayoshi Tanaka, Yoshinobu Baba, Noritada Kaji, Takao Yasui, Yuji Miyahara, Yukichi Horiguchi
  • Patent number: 10874751
    Abstract: Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: December 29, 2020
    Assignee: University of Notre Dame du Lac
    Inventors: Zihni Basar Bilgicer, Peter Edward Deak, Tanyel Kiziltepe Bilgicer, Jared Francis Stefanick, Jonathan Darryl Ashley
  • Patent number: 10857244
    Abstract: The present invention provides reagents and methods for detecting cancer and precancerous lesions in a patient.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 8, 2020
    Assignees: University of Washington Through Its Center for Communication, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Teresa A. Brentnall, Juergen Karl Willmann, Sheng Pan
  • Patent number: 10857237
    Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: December 8, 2020
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Mohammad Tariq Malik, Martin G. O'Toole, Paula J. Bates
  • Patent number: 10858396
    Abstract: The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 8, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Thomas D. Wang, Bishnu P. Joshi
  • Patent number: 10842846
    Abstract: The present disclosure provides peptides useful as inhibitors of the dimerization interface of EBNA1. The present disclosure also provides methods for treating and imaging EBV-associated cancers.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: November 24, 2020
    Assignee: Hong Kong Baptist University
    Inventors: Ka Leung Wong, Nai Ki Mak, Lijun Jiang
  • Patent number: 10835615
    Abstract: The invention described herein provides novel ampiphilic compounds that self-assemble into a hydrogel composition useful for treating wounds, including chronic wounds and diabetic wounds. The compounds of the invention have structural characteristics, such as hydrophilic and hydrophobic moieties, that enable self-assembly into discrete nanostructures, which then entangle to form the hydrogel. Also provided are methods for treating wounds.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: November 17, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Honggang Cui, Jeremy D. Walston, Peter M. Abadir, Ran Lin
  • Patent number: 10829423
    Abstract: A system and method for automatic production of astatine-211 labeled molecules is described. The invention represents a significant advantage in the preparation of At-211 radiopharmaceuticals including better reproducibility, reduced production time and increased radiation safety. The invention also enables routine automatic synthesis of radiopharmaceuticals in a clinical setting, in conjunction or at short distance from a cyclotron unit capable of producing the radionuclide.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: November 10, 2020
    Assignee: Alpha Therapy Solutions AB
    Inventors: Sture Lindegren, Emma Aneheim
  • Patent number: 10828390
    Abstract: The present invention relates to the technical field of reconstructive plastic surgery and cosmetology, and particularly to a biomimetic chitosan filler for preventing capsular contracture and preparation method thereof. The biomimetic chitosan filler for preventing capsular contracture includes chitosan gel, cross-linked sodium hyaluronate, surfactant, isoosmotic regulator, autologous adipose-derived stem cells, pH adjusting agent and water. The amount of the pH adjusting agent is to adjust a pH value of the chitosan filler to be within a range of 6.5-7.5. The chitosan filler prepared according to the present invention can reduce the inflammation caused by post-operative silica gel exudation, and prevent the occurrence and development of capsular contracture.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: November 10, 2020
    Assignee: SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Kun Zhang, Wanhua Chen, Bingqian Bu, Jianying Wu, Jundong Zhang, Zhen Chang, Peng Du
  • Patent number: 10821196
    Abstract: The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: November 3, 2020
    Assignee: Siemens Medical Solutions USA, Inc.
    Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Umesh B. Gangadharmath, Gang Chen, Vani P. Mocharla, Dhanalakshmi Kasi, Peter J. H. Scott, Qianwa Liang
  • Patent number: 10815200
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 27, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jens Cardinale, Martin Schaefer, Klaus Kopka, Matthias Eder, Ulrike Bauder-Wuest, Michael Eisenhut, Martina Benesova, Uwe Haberkorn, Frederik L. Giesel
  • Patent number: 10815530
    Abstract: A theranostic composition and method for determining the cell-specific potency of drugs is provided. Further, compositions and methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: October 27, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Avi Schroeder, Zvi Yaari
  • Patent number: 10807977
    Abstract: The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the composition comprises a compound of Formula (I) or a compound of Formula (II). The selective killing of senescent cells may delay aging and/or treat age-related disorders.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 20, 2020
    Assignee: BioVentures, LLC
    Inventors: Guangrong Zheng, Daohong Zhou, Xuan Zhang, Yingying Wang, Jianhui Chang
  • Patent number: 10806804
    Abstract: The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 20, 2020
    Assignee: Washington University
    Inventors: Samuel Achilefu, Kexian Liang, Rui Tang
  • Patent number: 10792366
    Abstract: Provided herein are methods for reducing clearance of nanotherapeutic agents from a subject, wherein the methods comprise administering a nutrition supplement to the subject prior to administration of the nanotherapeutic agent in the treatment of a disease. Methods for improving the bioavailability of the nanotherapeutic agent, methods of reducing the toxicity of the nanotherapeutic agent, and kits comprising the nutrition supplement and nanotherapeutic agent are also provided.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: October 6, 2020
    Assignee: Carnegie Mellon University
    Inventors: Chien Ho, Li Liu, Qing Ye
  • Patent number: 10793595
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: October 6, 2020
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDA
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 10786465
    Abstract: A composition comprising a nanoparticle, wherein the nanoparticle comprises a polymer/copolymer conjugated to a moiety is disclosed. A method of forming a nanostructure includes stirring poly(lactide-co-glycolide (PLGA) and 11-Ethyl-3-(dimethylaminopropyl) carbodiimide (EDC) in CH2Cl2 to create a PLGA mixture, n-boc-ethyelenediamine and N,N-Diisopropylethylamine (DIEA) are added to the PLGA mixture to create a reaction mixture. The reaction mixture is then precipitated in cold diethyl ether to form a purified polymer, which is then dried. The dried and purified polymer is then reconstituted in CH2Cl2:TFA solution and stirred under inert conditions. The product of the reconstituting step is evaporated to form a clear viscous residue that is dissolved in CH2Cl2 and then precipitated in cold ether to form a polymer. These functional polymers can encapsulate a variety of bioactives forming nanosystems improving the performance of bioactives.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 29, 2020
    Assignee: The Texas A&M University System
    Inventors: Naga Venkata Ravi Kumar Majeti, Raghu Ganugula, Meenakshi Arora, Prabhjot Saini
  • Patent number: 10787520
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 29, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang